Beilerli, A.,
Gareev, I.,
Beylerli, O.,
Yang, G.,
V.N. Pavlov,
Aliev, G.,
Ahmad, A. (2022) further makes them suitable as
cancer biomarkers. Studies involving human tumors have verified differences
Despite many advances in diagnosis and therapy (surgery, radiation therapy, chemotherapy),
cancer permeability and signaling inside cells. Several types of claudins are dysregulated in various
cancersGilyazova, I.R.,
Ivanova, E.A.,
Bermisheva, M.A.,
Loginova, M.V.,
Asadullina, D.D.,
Ishemgulov, R.R.,
Mustafin, A.T.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2022) of PTEN, rs17878362 of TP53, and rs2699887 of PIK3CA with the risk of prostate
cancer development. As a
Ahmad, S.,
Abbas, M.,
Ullah, M.F.,
Aziz, M.H.,
Beylerli, O.,
Alam, M.A.,
Syed, M.A.,
Uddin, S.,
Ahmad, A. (2022) Cancer metastasis is a major reason for the
cancer-associated deaths and a role of long non
Beilerli, Aferin,
Begliarzade, Sema,
Sufianov, Albert,
Ilyasova, Tatiana,
Liang, Yanchao,
Beylerli, Ozal (2022) Background: Ovarian
cancer (OC) is the most common malignant neoplasm of the female reproductive
Mingazheva, E.T.,
Prokofyeva, D.S.,
Valova, Ya.V.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Valiev, R.R.,
Ekomasova, N.V.,
Faishanova, R.R.,
Romanova, A.R.,
Khusnutdinova, E.K. (2022) The high risk of ovarian
cancer is primarily associated with mutations in BRCA1 and BRCA2 genes
Роль неоадъювантной гормонотерапии в лечении рака молочной железы: что мы знаем на данный момент?В. В. Воротников,
V. V. Vorotnikov,
Р. А. Пахомова,
R. A. Pakhomova,
А. В. Сойнов,
A. V. Soinov,
А. С. Гунина,
A. S. Gunina,
И. В. Копытич,
I. V. Kopytich,
М. Г. Цой,
M. G. Tsoi,
С. А. Абдугаффоров,
S. A. Abdugafforov (Креативная хирургия и онкология, №3, 2022) Preoperative Hormone Therapy in the Treatment of Breast
Cancer: What Do We Know So Far?